Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
October 02, 2024 07:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an...
SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encouraged to Contact the Firm
September 20, 2023 15:09 ET
|
Morris Kandinov, LLP
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Emergent BioSolutions Inc., James River Group...
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
July 06, 2022 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Sujata Dayal as a Class II director to...
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
June 24, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License...
Emergent BioSolutions to Participate in Investor Conferences
June 02, 2022 08:20 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
May 16, 2022 06:32 ET
|
Emergent BioSolutions
Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
May 12, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions Provides Corporate Governance Update
March 23, 2022 16:05 ET
|
Emergent BioSolutions
Zsolt Harsanyi, Ph.D. Appointed Chairman of the BoardKeith Katkin Appointed to the BoardEliminates Role of Executive ChairmanAppoints New Chairs of Audit, Strategic Operations, and Scientific Review...
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
January 14, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April...
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
January 09, 2022 14:00 ET
|
Emergent BioSolutions
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA...